Ka la 10 Hlakola 2025, CARsgen Therapeutics e phatlalatsa hore motho oa pele ea phekoloang ka phekolo ea allogeneic BCMA CAR-T e ntlafalitsoeng sethaleng sa THANK-u Plus™, o fihletse karabelo e tiileng e felletseng (sCR) le ho se be le lefu le setseng (MRD) tlhahlobong ea Letsatsi la 28. Sethala sa THANK-u Plus™ se ntlafalitsoe ka hare ho sona, ke theknoloji e ncha ea allogeneic CAR-T e etselitsoeng ho hlola liphephetso tsa phihlello kalafong ea CAR-T.
Mokuli, ea fumanoeng a e-na le myeloma e ngata e khutlelang morao/e sa hlaseleng, mofuta oa IgA-λ (R-ISS Stage II), o kile a feta mela e meraro ea phekolo e kopaneng hammoho le ho kenngoa ha sele ea stem ea hematopoietic ea autologous. Kamora ho tsoela pele ha lefu ka mor'a kalafo ea morao-rao, mokuli o ile a ngolisoa tekong ea bongaka. Kamora ho kenngoa ha lisele tsa CAR T boemong bo tlase ka ho fetisisa ho latela protocol ea bongaka, mokuli o ile a ba le lefu la ho lokolloa ha cytokine la Kereiti ea 1 (CRS), le ileng la laoloa ka katleho ka li-antipyretics le tocilizumab, 'me mokuli ha aa ka a bontša immune effect cell-associated neurotoxicity syndrome (ICANS) kapa liketsahalo tse ling tse mpe tse amanang le' mele tse amanang le CAR-T, tse bontšang boemo bo botle ba polokeho ka kakaretso.
Kalafo ena ea CAR-T e etselitsoe ho phekola myeloma e khutlisetsoang morao/e sa pheleng hantle (R/R MM) le leukemia ea sele ea plasma e khutlisetsoang morao/e sa pheleng hantle (R/R PCL). Lintlafatso tse ling tsa data li lebelletsoe karolong ea bobeli ea selemo sena.
Hona jwale, ho ntse ho na le diteko tse ngata tsa bongaka tsa mahlale a matjha a ho lwantsha kankere Chaena a batlang bakudi. Dipuisano mabapi le meriana le mahlale a matjha, o ka ikopanya le Lefapha la Matjhaba la Sepetlele sa Oncology sa Beijing Region South.
Nomoro ea mohala: 4008803716
Email：myimmnet@163.com
Litšupiso
2.https://www.prnasia.com/
Nako ea poso: Hlakola-11-2025